NAS:MTEM (USA) Also trade in: Germany

Molecular Templates Inc

$ 7.6 0.11 (1.47%)
Volume: 62,612 Avg Vol (1m): 82,230
Market Cap $: 279.46 Mil Enterprise Value $: 199.04 Mil
P/E (TTM): 0.00 P/B: 2.93
Earnings Power Value -17.76
Net Current Asset Value 1.27
Tangible Book 1.89
Projected FCF -4.42
Median P/S Value 11.69
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 26.46
Cash-To-Debt ranked lower than
54.92% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
MTEM: 26.46
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 13.6, Med: 10000, Max: 10000
Current: 26.46
13.6
10000
Equity-to-Asset 0.68
Equity-to-Asset ranked higher than
69.46% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
MTEM: 0.68
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.86, Med: 0.75, Max: 0.88
Current: 0.68
-0.86
0.88
Debt-to-Equity 0.03
Debt-to-Equity ranked higher than
84.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
MTEM: 0.03
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.03, Med: 0.04, Max: 0.07
Current: 0.03
-0.03
0.07
Debt-to-EBITDA -0.12
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
MTEM: -0.12
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.16, Med: -0.14, Max: -0.12
Current: -0.12
-0.16
-0.12
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.75
DISTRESS
GREY
SAFE
Beneish M-Score -1.50
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -140.22%
WACC 18.32%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -142.67
Operating Margin ranked lower than
67.17% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
MTEM: -142.67
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -48445.16, Med: -233.34, Max: 35.01
Current: -142.67
-48445.16
35.01
Net Margin % -140.03
Net Margin ranked lower than
69.07% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
MTEM: -140.03
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -41375.81, Med: -227.98, Max: 56.97
Current: -140.03
-41375.81
56.97
ROE % -31.79
ROE ranked lower than
52.88% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
MTEM: -31.79
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -544.3, Med: -79.34, Max: 519.53
Current: -31.79
-544.3
519.53
ROA % -23.14
ROA ranked lower than
54.34% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
MTEM: -23.14
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -132.78, Med: -48.97, Max: 71.8
Current: -23.14
-132.78
71.8
ROC (Joel Greenblatt) % -409.63
ROC (Joel Greenblatt) ranked lower than
66.51% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
MTEM: -409.63
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -11023.53, Med: -3213.19, Max: 6051.24
Current: -409.63
-11023.53
6051.24
3-Year Total Revenue Growth Rate -44.30
3-Year Revenue Growth Rate ranked lower than
83.56% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
MTEM: -66.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -100, Max: 454.3
Current: -66.1
0
454.3

» MTEM's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MTEM

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare NAS:CDMO NAS:EVLO NAS:SBBP NAS:KALA NAS:KOD LSE:ARIX LSE:BVXP SHSE:603139 NAS:DOVA NAS:MRNS NAS:HARP SZSE:000004 WAR:MAB XKLS:7090 WAR:SLV NAS:VRCA XKRX:087010 TSE:2183 NAS:CDXC BOM:512529
Traded in other countries NZW2.Germany
Address 9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. The company's product candidate portfolio includes evofosfamide to treat pancreatic cancer, glioblastoma, biliary tract cancer, and various solid tumors; and TH-3424 to treat liver cancer, castration-resistant prostate cancer, and T-cell acute lymphoblastic leukemias.

Ratios

Current vs industry vs history
PB Ratio 2.93
PB Ratio ranked higher than
74.95% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
MTEM: 2.93
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.23, Med: 2.32, Max: 66.68
Current: 2.93
0.23
66.68
PS Ratio 12.36
PS Ratio ranked higher than
54.55% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
MTEM: 12.36
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.26, Med: 19.05, Max: 4777.14
Current: 12.36
0.26
4777.14
EV-to-EBIT -7.48
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
MTEM: -7.48
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -22.4, Med: -2.05, Max: 8.7
Current: -7.48
-22.4
8.7
EV-to-EBITDA -7.80
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
MTEM: -7.8
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -23.3, Med: -2.1, Max: 8.4
Current: -7.8
-23.3
8.4
EV-to-Revenue 10.03
EV-to-Revenue ranked lower than
56.81% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
MTEM: 10.03
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -15.5, Med: 17, Max: 4493.5
Current: 10.03
-15.5
4493.5
Current Ratio 3.24
Current Ratio ranked higher than
50.74% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
MTEM: 3.24
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.48, Med: 5.16, Max: 13.48
Current: 3.24
1.48
13.48
Quick Ratio 3.24
Quick Ratio ranked higher than
53.35% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
MTEM: 3.24
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.48, Med: 5.16, Max: 13.48
Current: 3.24
1.48
13.48
Days Sales Outstanding 5.44
Days Sales Outstanding ranked lower than
96.11% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
MTEM: 5.44
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 5.44, Med: 179.7, Max: 972.69
Current: 5.44
5.44
972.69

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -65.80
3-Year Share Buyback Rate ranked lower than
89.61% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
MTEM: -65.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -729.1, Med: -56.9, Max: -6.6
Current: -65.8
-729.1
-6.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.02
Price-to-Tangible-Book ranked higher than
65.66% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
MTEM: 4.02
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.4, Med: 2.59, Max: 13.38
Current: 4.02
0.4
13.38
Price-to-Median-PS-Value 0.65
Price-to-Median-PS-Value ranked higher than
77.29% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
MTEM: 0.65
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 0.99, Max: 73.89
Current: 0.65
0.03
73.89
Earnings Yield (Joel Greenblatt) % -13.44
Earnings Yield (Greenblatt) ranked lower than
75.76% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
MTEM: -13.44
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -192828.6, Med: -17.95, Max: 163390.7
Current: -13.44
-192828.6
163390.7

More Statistics

Revenue (TTM) (Mil) $ 19.81
EPS (TTM) $ -0.9
Beta 2.63
Volatility % 65.14
52-Week Range $ 3.19 - 7.9
Shares Outstanding (Mil) 36.77

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N